Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
502
Views
5
CrossRef citations to date
0
Altmetric
Articles

Central nervous system involvement by mantle cell lymphoma

Nicole McLaughlina Department of Internal Medicine, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-2197-6147
ORCID Icon,
Yucai Wangb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Thomas Witzigb Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0002-4215-6500
ORCID Icon,
Jose Villasboasb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Thomas Habermannb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
David Inwardsb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Nora Bennanib Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0001-8358-5953
ORCID Icon,
Gita Thanarajasingamb Division of Hematology, Mayo Clinic, Rochester, MN, USAORCID Iconhttps://orcid.org/0000-0003-2144-5415
ORCID Icon,
Grzegorz Nowakowskib Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Luis Porratab Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Carrie Thompsonb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Ivana Micallefb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Patrick Johnstonb Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Stephen Ansellb Division of Hematology, Mayo Clinic, Rochester, MN, USA
&
Jonas Paludob Division of Hematology, Mayo Clinic, Rochester, MN, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7350-5531
ORCID Icon show all
Pages 371-377 | Received 21 Jul 2022, Accepted 29 Oct 2022, Published online: 23 Nov 2022

References

  • Li S, Xu J, You MJ. The pathologic diagnosis of mantle cell lymphoma. Histol Histopathol. 2021;36(10):1037–1051.
  • Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97(3):586–591.
  • Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013;24(8):2119–2123.
  • Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–5043.
  • Chihara D, Asano N, Ohmachi K, et al. Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol. 2015;26(5):966–973.
  • Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOB 0213. Ann Oncol. 2013;24(6):1587–1593.
  • Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the groupe d’Etude des lymphomes de l’Adulte. Blood. 2013;121(1):48–53.
  • Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575.
  • Owen C, Berinstein NL, Christofides A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–e240.
  • Tucker D, Naylor G, Kruger A, et al. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement – a multi-centre case series from the United Kingdom. Br J Haematol. 2017;178(2):327–329.
  • Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared to chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022;140(17):1907–1916.
  • Olszewski A, Chorzalska A, Petersen M, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021;5(24):5525–5535.
  • Karschnia P, Rejeski K, Winkelmann M, et al. Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells. Neurology. 2022;98(21):884–889.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.